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Introduction
Idelalisib (Zydeligâ; Gilead Sciences, Inc., Foster City, CA; 
formerly GS-1101, CAL101) is a selective, oral, phosphati-
dylinositol 3-kinase delta (PI3Kd) inhibitor [1]. It is approved 
by the US Food and Drug Administration for the treatment 
of patients with relapsed chronic lymphocytic leukemia 
(CLL), in combination with rituximab, in patients for whom 
rituximab alone would be considered appropriate therapy 
due to other comorbidities; relapsed follicular B-cell non-
Hodgkin lymphoma in patients who have received  2 
prior systemic therapies; and relapsed small lymphocytic 
lymphoma in patients who have received  2 prior systemic 
therapies [2]. The recommended starting dose of idelalisib 
is 150 mg orally with or without food twice daily (BID) [2]. 
The European Commission has also granted marketing 
authorization for idelalisib: (1) in combination with ritux-
imab for the treatment of adult patients with CLL who 
have received  1 prior therapy or as first-line treatment 
in the presence of 17p deletion or TP53 mutation in 
patients unsuitable for chemoimmunotherapy and (2) 
as monotherapy in the treatment of adult patients with 
follicular lymphoma that is refractory to two prior lines of 
treatment [3]
PI3K–AKT–mTOR pathway and the role of PI3Kd
Surface-receptor tyrosine kinases activate class I PI3Ks [4], 
which regulate numerous cellular functions through phos-
phorylation of lipid second messengers [5]. Class I PI3Ks 
consist of four catalytic domains (p110a, p110b, p110g, 
p110d) [5]. The a and b isoforms are ubiquitously expressed, 
and the g isoform has multiple functions, including roles in 
T-cell development and signaling [5]. However, the d isoform 
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is predominantly found in leukocytes [6]. p110d integrates 
and transmits signals from surface proteins, including B-cell 
antigen receptors (BCRs) and chemokine receptors (CXCR4 
and CXCR5) responsible for CLL cell homing and retention 
in tissue compartments, via downstream activation of AKT 
(also known as protein kinase B) [7]. AKT is a central node 
in signaling cascades that regulate cell survival, proliferation 
and migration [4], and it is known to activate the pro-growth 
mammalian target of rapamycin (mTOR) complex (Figure 1) 
[4,7]. p110d plays an essential, non-redundant role in BCR 
signaling in vitro, and p110d-deficient mice show decreased 
numbers of mature B cells and defective humoral responses 
to immunization with minimal effect on other hematopoi-
etic cells [8]. Hyperactive BCR signaling has been implicated 
in non-Hodgkin lymphoma and CLL, suggesting that p110d 
may represent a useful target in B-cell malignancies [9,10].
Preclinical studies have shown that inhibition of PI3Kd-
dependent signaling with idelalisib resulted in decreased 
downstream signaling of BCR, CXCR4 and CXCR5 (i.e. 
decreased activation of AKT, mTOR and other downstream 
effectors) [1,7]. Consequently, exposure to idelalisib inhib-
ited proliferation, chemotaxis, motility, adhesion and sur-
vival and promoted apoptosis in cell lines derived from B-cell 
malignancies [1,7].
Idelalisib clinical data
Idelalisib has shown clinical activity and a tolerable safety 
profile in phase 2 and 3 trials.
Idelalisib in indolent non-Hodgkin lymphoma
A single-arm, open-label, phase 2 trial (NCT01282424) eval-
uated treatment with idelalisib 150 mg BID in 125 patients 
with double-refractory (to rituximab and an alkylating 
agent), indolent non-Hodgkin lymphoma (iNHL) until dis-
ease progression or study withdrawal. Idelalisib treatment 
resulted in an overall response rate (ORR; primary endpoint 
and determined by an Independent Review Committee 
[IRC]) of 57% (95% confidence interval [CI], 48–66%), a com-
plete response rate of 6%, a partial response rate of 50% and 
a minor response rate of 1% (one patient with Waldenström 
macroglobulinemia). The median duration of response was 
12.5 months (range, 0.03–14.8). The median progression-free 
survival (PFS) was 11.0 months (range, 0.03–16.6), with a PFS 
rate of 47% at 48 weeks. The median overall survival (OS) was 
20.3 months (range, 0.7–22.0), with an estimated OS rate of 
80% at 1 year. The most common adverse events (AEs) were 
diarrhea, nausea and fatigue. The most common labora-
tory abnormalities grade  3 were neutropenia and alanine 
aminotransferase (ALT) or aspartate aminotransferase (AST) 
elevation (Table I). The most common serious AEs ( 5%) 
were pyrexia (10%), pneumonia (7%) and diarrhea (7%). AEs 
led to treatment discontinuation in 25 patients (20%) and 
a dose reduction (100 mg BID or 75 mg BID) in 42 patients 
(34%) [11].
Idelalisib in CLL
Efficacy and safety of idelalisib were also demonstrated in 
a randomized, double-blind, placebo-controlled, phase 3 
trial (NCT01539512) in 220 patients with progressive CLL 
and either decreased renal function, previous therapy-
induced myelosuppression or major coexisting illness. 
Patients received 150 mg BID plus rituximab or placebo 
plus rituximab. At interim analysis, PFS as assessed by IRC 
demonstrated a statistically significant reduction in the 
risk of progression or death by 85% (adjusted hazard ratio 
[95% CI], 0.15 [0.08–0.28]; unadjusted p  0.0001); median 
Figure 1. Pathways utilizing PI3Kd signaling. AKT is the major downstream target of PI3Kd. Once phosphorylated, AKT is activated and in turn 
phosphorylates other downstream substrates, including mTOR. (Reproduced with permission from Gilead Sciences, Inc.) AKT, serine/threonine 
kinase (also known as protein kinase B); BCR, B-cell receptor; BTK, Bruton’s tyrosine kinase; CXCR, chemokine receptor; FAK, focal adhesion kinase; 
JAK, Janus kinase; LYN, Lyn tyrosine kinase; mTOR, mammalian target of rapamycin; NF, nuclear factor; PI3K, phosphatidylinositol 3-kinase; SFKs, 
Src-family kinases; STAT, signal transducer and activator of transcription; SYK, spleen tyrosine kinase; TRAF, TNF receptor associated factor.
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PFS was not reached in the idelalisib group, compared with 
5.5 months in the placebo group. At 24 weeks, the PFS rate 
was 93% in the idelalisib group, compared with 46% in the 
placebo group. At 1 year, the rate of OS was significantly 
higher in the idelalisib group (92%) compared with the 
placebo group (80%; adjusted hazard ratio for death [95% 
CI], 0.28 [0.09–0.86]; p  0.02); median OS was not reached 
in either group at the time of analysis. A significant improve-
ment in ORR was also observed in the idelalisib group 
compared with the placebo group (81% [95% CI, 71–88%] vs. 
13% [95% CI, 6–21%], respectively; p  0.001); all responses 
were partial responses. The five most common AEs in 
idelalisib-treated patients were pyrexia, fatigue, nausea, 
chills and diarrhea; grade  3 diarrhea was reported in 
four patients in the idelalisib group and no patients in the 
placebo group. The most common laboratory abnormalities 
grade  3 were neutropenia, thrombocytopenia, anemia and 
ALT or AST elevation (Table I). Serious AEs were reported in 
40% of patients in the idelalisib group and 35% of patients 
in the placebo group. The most common serious AEs ( 5%) 
in the idelalisib group were pneumonia (6%), pyrexia (6%) 
and febrile neutropenia (5%); in the placebo group, only 
pneumonia (8%) and febrile neutropenia (6%) were reported 
in  5% of patients. AEs led to treatment discontinuation in 
nine patients (8%) in the idelalisib group and 11 patients 
(10%) in the placebo group [12].
Idelalisib treatment-emergent adverse events
Idelalisib US prescribing information contains a black box 
warning for fatal and/or severe diarrhea or colitis, hepato-
toxicity, pneumonitis and intestinal perforation [2]. Identifi-
cation and management of diarrhea or colitis, transaminitis 
and pneumonitis are discussed in the following sections and 
based on experience from previously conducted studies and 
the US prescribing information; they do not involve any new 
studies of human or animal subjects performed by any of the 
authors.
Additional warnings and precautions from the US pre-
scribing information include severe cutaneous reactions, 
anaphylaxis, neutropenia and embryo-fetal toxicity. A case 
of toxic epidermal necrolysis (patient was receiving idelalisib 
in combination with rituximab and bendamustine) as well 
as other severe or life-threatening (grade  3) cutaneous 
reactions have been reported. The US prescribing informa-
tion recommends monitoring patients for the development 
of severe cutaneous reactions and, if they occur, discontinu-
ing idelalisib. Patients who develop serious allergic reactions, 
including anaphylaxis, should permanently discontinue 
treatment with idelalisib and institute appropriate support-
ive measures. Treatment-emergent grade 3 or 4 neutrope-
nia has been reported in 31% (234/760) of patients treated 
with idelalisib across clinical trials. Drug interruption 
occurred in 3.6% of patients, and 1.3% of patients required a 
dose reduction; two patients ( 0.5%) eventually discontin-
ued therapy. The median time to onset of grade  3 neutrope-
nia analyzed in the New Drug Application (NDA) integrated 
safety summary (n  642) was 1.4 months (range 0.0–13.8 
months). Granulocyte colony-stimulating factor (G-CSF) 
was permitted to treat patients with grade 3 or 4 treatment-
emergent neutropenia depending on the study protocol. In 
patients with relapsed CLL in the phase 3 clinical trial and in 
patients with iNHL in the phase 2 clinical trial, idelalisib was 
withheld in grade 4 treatment-emergent neutropenia that 
was not responding to G-CSF after 14 days (phase 3 trial) or 
3 days (phase 2 trial). In the phase 3 study, G-CSF was utilized 
in 24.6% of patients in the idelalisib plus rituximab group 
and in 19.4% of patients in the placebo plus rituximab group. 
In the phase 2 trial, G-CSF was used in 15.8% of patients 
given the 150 mg BID dose. Blood counts should be moni-
tored at least every 2 weeks for the first 3 months of therapy 
and at least weekly in patients whose neutrophil counts are 
 1.0  109/L [2]. Intestinal perforation including two fatal 
cases occurred in 6/1192 (0.5%) patients with hematological 
malignancies across phase 1, 2 and 3 clinical trials (including 
ongoing randomized phase 3 clinical trials). Two patients had 
Table I. Overview of adverse events reported in  20% of patients and key laboratory abnormalities in patients 
in any idelalisib group in phase 2 and 3 idelalisib studies [11,12].
Phase 3 study†
Phase 2 study* idelalisib 
only (n  125), n (%)
Idelalisib  rituximab 
(n  110), n (%)
Placebo  rituximab 
(n  107), n (%)
Any grade Grade  3 Any grade Grade  3 Any grade Grade  3
Adverse events 103 (82) 68 (54) 100 (91) 62 (56) 101 (94) 51 (48)
 Diarrhea‡ 54 (43) 16 (13) 21 (19) 4 (4) 15 (14) 0
 Nausea 37 (30) 2 (2) 26 (24) 0 23 (21) 0
 Fatigue 37 (30) 2 (2) 26 (24) 3 (3) 29 (27) 2 (2)
 Cough 36 (29) 0 16 (15) 0 27 (25) 2 (2)
 Pyrexia 35 (28) 2 (2) 32 (29) 3 (3) 17 (16) 1 (1)
 Chills 8 (6)§ 0§ 24 (22) 2 (2) 17 (16) 0
Laboratory abnormalities
 Neutropenia 70 (56) 34 (27) 60 (55) 37 (34) 52 (49) 24 (22)
 Anemia 35 (28) 2 (2) 28 (25) 6 (5) 32 (30) 15 (14)
 Thrombocytopenia 32 (26) 8 (6) 19 (17) 11 (10) 28 (26) 17 (16)
 ALT or AST elevation 62 (50)§ 16 (13)§ 38 (35) 6 (5) 20 (19) 1 (1)
 ALP elevation 28 (22) 0 14 (13)§ 0§ 17 (16)§ 0§
 ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase.
*In patients with indolent non-Hodgkin lymphoma.
†In patients with chronic lymphocytic leukemia.
‡Cited publications did not pool diarrhea and colitis adverse events.
§Data on file, Gilead Sciences, Inc., Foster City, CA.
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phase 3 CLL study (n  110; data cut-off, 9 October 2013) 
[2,12,13]. One fatality was reported among all patients who 
received idelalisib across all trials (n  1192). The fatality 
occurred in an ongoing phase 3 study in a patient who had 
diarrhea concomitantly with thrush and shingles as well as a 
positive test for Clostridium difficile, a possible cause of the 
diarrhea [13].
In patients with relapsed CLL who received idelalisib 
plus rituximab (n  110) in the phase 3 clinical trial, any 
grade diarrhea (includes preferred term colitis) was reported 
in 21% (placebo plus rituximab [n  108], 16%), grade  3 
diarrhea was reported in 5% (placebo plus rituximab, 0%) 
and serious diarrhea was observed in 5% of patients in 
the idelalisib plus rituximab treatment group. Diarrhea 
was one of the most common AEs that led to idelalisib dose 
reduction and treatment discontinuation [2]. Among 146 
patients with iNHL who received idelalisib 150 mg mono-
therapy, any grade diarrhea (includes preferred terms 
colitis, enterocolitis and gastrointestinal inflammation) 
was reported in 47%, grade  3 diarrhea in 14% and serious 
diarrhea in 11%. Diarrhea was one of the most common AEs 
that led to idelalisib dose interruption or discontinuation 
(11% of patients) [2].
For cases of moderate diarrhea (increase of 4–6 stools/
day over baseline; grade 2), the idelalisib US prescribing 
information recommends maintaining idelalisib dose and 
monitoring at least once weekly until resolved. For 
cases of severe diarrhea (increase of  7 stools/day over 
baseline; grade 3) or hospitalization due to diarrhea, the 
US prescribing information recommends withholding 
idelalisib and monitoring at least once weekly until the 
diarrhea resolves; once resolved, idelalisib may be resumed 
at a reduced dose of 100 mg BID. If life-threatening diar-
rhea (grade 4) occurs, idelalisib should be permanently 
discontinued [2].
Enteric budesonide has been a commonly used treat-
ment for severe diarrhea or colitis, resulting in a relatively 
shorter time to resolution. Among the 106 previously men-
tioned cases of severe diarrhea or colitis (grade  3), 23 were 
treated with enteric budesonide; however, budesonide use 
may be underreported in this population. To date, sufficient 
information is available to calculate time to resolution for 
18 cases in which diarrhea or colitis was considered a non-
infectious, serious AE attributable to idelalisib. The mean 
time to resolution after initiation of enteric budesonide 
was 12.1 days (range, 1–35 days) [13]. All cases of diarrhea or 
colitis resolved with drug withdrawal. For grade  3 diarrhea 
or colitis, 71 of 106 cases were rechallenged with idelalisib, 
with a success rate of 58% (41/71).
An expert panel of 10 hematologists and one gastroenter-
ologist was convened in May 2014 to discuss the character-
istics of idelalisib treatment-emergent diarrhea/colitis and 
to propose clinical management recommendations for 
healthcare providers. The predetermined and primary 
focus of the panel’s discussions and recommendations was 
diarrhea that responds poorly to antidiarrheal or empiric 
antimicrobial therapy. During the open discussion, the 
panel reached unanimous conclusions, which are outlined 
here. Differences of opinion were thoroughly discussed and 
previously reported having diarrhea or colitis. One patient 
(idelalisib plus rituximab arm) developed grade 3 colitis 
on day 119, which subsequently led to a left colon perfora-
tion on day 198. One patient developed diarrhea, colitis and 
duodenitis, followed by microscopic bowel perforation 
without specified location on day 519. Both patients had 
concomitant prednisolone use at the time of bowel perfora-
tion. Two patients had underlying gastrointestinal malignan-
cies; one patient had colon cancer with tumor perforation 
confirmed at autopsy, and the other patient had underlying 
pancreatic cancer with right colon perforation on day 224, 
preceded by grade 4 colitis. Two patients had perforated 
diverticulitis; one patient had no preceding diarrhea or 
colitis, and the other patient developed sigmoid colon diver-
ticulum perforation on day 126 preceded by diverticulitis 
and diarrhea [13].
Diarrhea or colitis
Severe diarrhea or colitis (grade  3) has occurred in patients 
treated with idelalisib [2]. It is unknown whether this is a 
class effect of PI3K inhibitors; however, grade  3 diarrhea 
has been reported in a clinical trial with IPI-145, a dual g/d 
PI3K inhibitor [14]. Among idelalisib-treated patients who 
reported diarrhea or colitis, the median time to onset of any 
grade diarrhea or colitis was 1.9 months (range, 0.0–29.8), of 
grade 1 or 2 was 1.5 months (range, 0.0–15.2) and of grade 3 
or 4 was 7.1 months (range, 0.5–29.8). Kaplan–Meier curves 
of time to onset of diarrhea or colitis are shown for all idela-
lisib-treated patients in Figure 2 [13]. Idelalisib-associated 
severe diarrhea responds poorly to antimotility agents; 
however, median time to resolution ranged between 1 week 
and 1 month across trials following interruption of idelalisib 
treatment and, in some instances, initiation of corticosteroid 
treatment [2].
Severe diarrhea or colitis occurred in 106/760 (14%) 
patients from the NDA 90-day safety update for phase 
1 and 2 studies (n  650; data cut-off, 9 September 2013) 
plus patients who received idelalisib plus rituximab in the 
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Figure 2. Kaplan–Meier time to onset of any grade or grade  3 diarrhea 
or colitis in patients treated with idelalisib. The vertical, dotted lines 
represent median time to onset of any grade diarrhea or colitis (blue) 
and grade  3 diarrhea or colitis (red) calculated based on all patients 
with an event.
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in all cases consensus recommendations were subsequently 
achieved.
First, the two types of diarrhea observed in idelalisib 
clinical trials were evaluated. The first type of diarrhea 
tends to be self-limiting. This type generally occurs within 
the first 8 weeks and is typically mild or moderate (grade 
1–2) and responsive to common antidiarrheal agents. 
The second type of diarrhea, the predetermined panel 
focus, tends to occur relatively late (although a few cases 
happened early) and responds poorly to antidiarrheal or 
empiric antimicrobial therapy; it is considered most likely 
to be idelalisib related. The idelalisib-related diarrhea may 
be sudden or gradual in onset and is usually watery, with-
out cramps, devoid of blood or mucus and culture negative. 
Several colonoscopies in patients with idelalisib treatment-
emergent, late-onset diarrhea revealed histologic appear-
ance of the colon consistent with that of lymphocytic colitis. 
Although a definitive underlying mechanism for treatment-
emergent diarrhea is unknown, similar histologic findings 
were noted in a murine PI3Kd knock-out model [15]. Anec-
dotally, these cases were responsive to budesonide and/
or systemic corticosteroid (e.g. prednisone) treatment; in 
some cases, prednisolone 1 mg/kg was administered with 
tapering off once diarrhea returned to grade 1. The time to 
resolution of severe diarrhea appeared to be shorter with 
the initiation of budesonide and/or systemic corticoster-
oids (1–2 weeks) compared with idelalisib interruption 
alone (approximately 1 month).
Patients taking idelalisib should be evaluated for any 
grade diarrhea. For those presenting with diarrhea, a thor-
ough history, physical examination and necessary laboratory 
testing should be performed during the initial patient exami-
nation (Table II). Diagnostic colonoscopy should be reserved 
for atypical cases (e.g. bloody diarrhea) or those in whom 
the recommended treatment interventions do not lead to 
resolution of diarrhea.
The expert panel used a previous set of guidelines for the 
management of diarrhea induced by cancer treatment [16] 
as a starting point to develop recommendations for com-
munity practitioners to implement in cases of idelalisib 
treatment-emergent diarrhea. Self-limiting, uncomplicated 
diarrhea (grade 1 and some cases of mild grade 2) can usu-
ally be managed with antidiarrheal therapy (e.g. loperamide) 
and diet modification. However, frequent reassessments 
are needed to ensure that unresolved diarrhea is managed 
more aggressively (Figure 3).
Idelalisib-related, late-onset, grade 2 diarrhea (includ-
ing borderline grade 3 diarrhea) in patients taking idelalisib 
Table II. Evaluation and diagnostic testing recommendations for idelalisib-treated patients presenting with 
diarrhea (any grade).
History and physical examination Laboratory testing
Physical examination including assessment of patient •	
for fever, dizziness, abdominal pain/cramping 
and weakness (i.e. rule out risk for sepsis, bowel 
obstruction, dehydration)
History of onset and duration of diarrhea•	
Travel history•	
Description of number of stools and stool composition •	
(e.g. watery, bloody, nocturnal)
Medication profile to identify diarrheogenic agents•	
Dietary profile to identify diarrheogenic foods•	
Stool work-up•	
Occult blood determination•	
Culture for enteric pathogens •	
(Salmonella, Escherichia coli, 
Campylobacter, infectious colitis)
•	 Clostridium difficile
CBC, electrolytes and BUN/Cr•	
Consider colonoscopy in selected cases•	
 BUN, blood urea nitrogen; CBC, complete blood count; Cr, creatinine.
Figure 3. Management algorithm for grade 1–2 uncomplicated diarrhea. (Adapted in part with permission from reference [16].).
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combination with ofatumumab in an ongoing phase 3 clini-
cal trial [13]. The cause of death was determined to be acute 
liver failure and, at the time of death, the patient also had 
grade 4 sepsis [13]. Most (74%) patients with ALT/AST 
elevation resumed idelalisib treatment at a lower dose 
without recurrence; however, 26% of patients had a recur-
rence of ALT and AST elevation despite the lower dose [2].
In patients with relapsed CLL treated with idelalisib plus 
rituximab (n  110) in the phase 3 clinical trial, any grade ALT 
and AST increase occurred in 35% (placebo plus rituximab, 
10%) and 25% (placebo plus rituximab, 14%) of patients, 
respectively; grade 3–4 elevations occurred in 8% (placebo 
plus rituximab, 1%) and 5% (placebo plus rituximab, 0%). 
Hepatotoxicity was one of the most common AEs that led 
to idelalisib dose reduction and treatment discontinuation. 
In patients with iNHL taking idelalisib 150 mg monother-
apy (n  146), any grade ALT increase occurred in 50% of 
patients, grade 3 in 14% and grade 4 in 5%; any grade AST 
increase occurred in 41% of patients, grade 3 in 8% and grade 
4 in 4%. Elevations in transaminases were one of the most 
common causes of treatment interruption or discontinua-
tion (10% of patients) [2].
Although the expert panel did not discuss manage-
ment of transaminitis in patients taking idelalisib, the US 
prescribing information states that idelalisib should not be 
used concomitantly with other hepatotoxic drugs. Further, 
it recommends monitoring ALT and AST every 2 weeks for 
the first 3 months of treatment, every 4 weeks for the next 
3 months of treatment and then every 1–3 months thereaf-
ter. The frequency of monitoring should be weekly in any 
instance of ALT or AST  3  ULN until resolved. For ALT/
AST elevation  3–5  ULN, the US prescribing information 
recommends maintaining the idelalisib dose and monitor-
ing at least once weekly until levels are  1  ULN. For cases 
of ALT/AST  5–20  ULN, it is recommended to withhold 
idelalisib and monitor ALT/AST at least once weekly until 
is considered clinically significant and should be managed 
in a similar manner to grade  3; this is especially true for 
any grade 2 diarrhea that is unresponsive to antimotility 
agents after 24 h. For idelalisib-related diarrhea or coli-
tis (including unresolved grade 2 and grade  3), initial 
management should include diagnostic testing to rule out 
infectious causes (Figure 4). After exclusion of infectious 
causes, initiation of budesonide or oral or intravenous ste-
roid therapy is recommended. The duration of budesonide 
therapy should be based on individual clinical response. In 
general, it should be continued until complete resolution 
of diarrhea, but it should not be used for chronic suppres-
sion of symptoms associated with ongoing use of idelalisib. 
Treatment should be individualized based on a patient’s 
age, comorbidities and social/family support. For example, 
an elderly patient or one who lives alone may need to 
be hospitalized for observation, whereas a patient with 
adequate family/caregiver support may be able to have 
in-home management.
The expert panel concluded that healthcare profession-
als should advise patients and caregivers that diarrhea of 
any grade while taking idelalisib is a reportable symptom. 
The panel agreed that patients should call their doctor at the 
first sign of diarrhea, stay well hydrated and implement 
recommendations for diet modification (Table III).
Transaminitis
Serious, including fatal, hepatotoxicity has occurred in 
patients treated with idelalisib. Elevations in ALT or 
AST  5  the upper limit of normal (ULN) have been 
observed, usually occurring within the first 12 weeks of 
treatment. Most transaminase elevations were reversible 
with dose interruption for idelalisib-treated patients [2].
Across idelalisib clinical trials, serious hepatotoxic-
ity occurred in 109/760 (14%) patients, with one fatality 
reported (1/1192) in a patient who was receiving idelalisib in 
Figure 4. Management algorithm for unresolved grade 2 and grade 3/4 diarrhea. IV, intravenous; PO, per os. *Recommended dosage: three 3 mg 
capsules PO once daily (9 mg total) [23]. †Based on panel members’ experience in clinical trials, prednisolone 1 mg/kg has been used with tapering 
off once diarrhea returns to grade 1.
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monitis with idelalisib use are consistent with the drug-
induced pneumonitis associated with mTOR inhibitors 
(e.g. everolimus, sirolimus and temsirolimus) and therefore 
warrant consideration. Although the mechanisms underly-
ing development of drug-induced pneumonitis in patients 
taking mTOR inhibitors are not fully understood, hypoth-
eses include immune-mediated, host-mediated and dose- 
dependent processes. An expert panel of nephrologists, 
urologists, medical oncologists and pulmonologists was 
convened in 2012 to discuss the management of pneu-
monitis associated with mTOR inhibition. Primary recom-
mendations included education of patients and healthcare 
professionals for prompt recognition and proper manage-
ment of this AE. The panel advised that mTOR therapy 
should be initiated with caution in patients with pre-existing 
interstitial lung disease, significant pulmonary fibrosis or 
severe chronic obstructive pulmonary disease because a 
poorer prognosis for drug-induced pneumonitis would be 
expected in these patients. After diagnosis, management of 
drug-induced pneumonitis should consist of grading the 
toxicity, establishing a monitoring schedule, reconsidering 
the dose of the mTOR inhibitor (or interrupting or discon-
tinuing therapy), utilizing other treatments as warranted 
and determining the need for referral [17]. Although the 
recommendations of this expert panel cannot be formally 
applied to patients with idelalisib-associated pneumonitis, 
they provide a framework for future considerations.
Conclusion
Idelalisib has recently been approved by the US Food and 
Drug Administration and European Commission. In clini-
cal trials, it has demonstrated significant efficacy and an 
acceptable safety profile in indolent B-cell malignancies. 
Clinically, the selectivity of idelalisib for the d isoform has 
the potential to reduce off-target effects compared with 
non-selective PI3K inhibitors [18,19].
Diarrhea or colitis, transaminitis and pneumonitis are 
three clinically significant idelalisib treatment-emergent 
AEs that warrant further investigation. An expert panel of 
hematologists concluded that any grade diarrhea while 
taking idelalisib is a reportable symptom and idelalisib-
related, late-onset, grade 2 diarrhea (including borderline 
grade 3 diarrhea) should be managed in a similar manner 
to grade  3. The US prescribing information recommends 
that idelalisib should not be used concomitantly with 
levels are  1  ULN; once this occurs, idelalisib may be 
resumed at a reduced dose of 100 mg BID. If ALT/AST eleva-
tion  20  ULN occurs, idelalisib should be permanently 
discontinued [2].
Pneumonitis
Pneumonitis, including fatal cases, has occurred in patients 
treated with idelalisib [2]. Across clinical trials, pneumonitis 
occurred in 24/760 (3%) idelalisib-treated patients and of 
these, 19 cases were reported as serious AEs. Fatalities due 
to pneumonitis were reported in 3/760 patients ( 0.5%) 
[13]. Two deaths occurred in elderly patients with previ-
ously untreated CLL who received idelalisib concurrently 
with rituximab. An autopsy in one patient revealed findings 
consistent with late changes of acute respiratory distress 
syndrome for which a pulmonary hypersensitivity to idela-
lisib and/or rituximab was a reasonable possibility. The 
third fatality occurred in a 52-year-old patient who received 
idelalisib monotherapy for follicular lymphoma and had 
been previously exposed to rituximab and bendamustine 
for 17 months prior to idelalisib exposure. Lung wedge 
biopsy revealed changes consistent with hypersensitivity 
pneumonitis [13].
In a phase 3 study of idelalisib plus rituximab in patients 
with CLL, pneumonitis occurred in 4% (4/110) of patients 
(placebo plus rituximab, 1/110 [1%]); no grade  3 pneu-
monitis was reported in either group [12]. In the phase 2 
iNHL study, 3/125 (2%) patients developed serious pneu-
monitis [11].
The expert panel did not discuss management of pneu-
monitis; however, the US prescribing information recom-
mends that any patient taking idelalisib who presents with 
pulmonary symptoms such as cough, dyspnea, hypoxia, 
interstitial infiltrates on a radiologic examination or a decline 
in oxygen saturation by  5% should be evaluated for pneu-
monitis. If pneumonitis is suspected, idelalisib treatment 
should be interrupted until the cause is determined. Idela-
lisib should be discontinued with any severity of symptom-
atic pneumonitis [2]. Appropriate and extensive evaluations 
should be performed for infectious etiologies of pneumoni-
tis, including testing for Pneumocystis jirovecii pneumonia 
in patients with CLL. In clinical trials, some patients have 
been treated with corticosteroids in addition to continuing 
antibiotics if their pneumonitis had not improved.
Currently there are no data to define the mechanism of 
idelalisib-related pneumonitis; however, reports of pneu-
Table III. Diet modification recommendations for patients with idelalisib treatment-emergent diarrhea [21,22].
Diet modifications
Drink plenty of fluids, 8–12 glasses a day of oral-rehydration drinks (e.g. Gatorade•	 â, Poweradeâ, Pedialyteâ), 
other clear liquids or clear broth to replace lost fluids and minerals
Eat 5–6 small meals each day•	
Eat low-fat, high-protein foods such as lean meat and eggs•	
Try BRAT (bananas, rice, apple sauce, toast) diet to help lessen the number of bowel movements•	
Try crackers, gelatin, noodles or oatmeal•	
Eat cooked instead of raw vegetables, and remove skins from fruits before eating•	
Avoid fried, fatty, greasy or spicy foods•	
Avoid milk (if it makes the diarrhea worse), milk products (including ice cream) and acidic drinks  •	
(e.g. tomato juice, citrus juices, fizzy soft drinks)
Avoid foods that cause gas (e.g. broccoli and cabbage) and high-fiber foods•	
Avoid caffeine, alcohol and herbal supplements (some may cause diarrhea)•	
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other hepatotoxic drugs and serum transaminase levels 
should be evaluated at regular intervals during idelalisib 
treatment to identify signs of hepatotoxicity. Any patient 
presenting with pulmonary symptoms should be evaluated 
for pneumonitis.
It is worth noting that a number of drug interactions have 
been associated with idelalisib. Coadministration of idelal-
isib with the strong cytochrome P4503A (CYP3A) inducer, 
rifampin, decreased the area-under-the-curve (AUC) and 
peak concentration (Cmax) of idelalisib. Moreover, coadmin-
istration of idelalisib with the sensitive CYP3A substrate, 
midazolam, increased the AUC and Cmax of midazolam 
[2,20]. Thus, idelalisib should not be coadministered with 
CYP3A substrates or strong CYP3A inducers [2].
Overall, although the US prescribing information carries 
black box warnings for fatal and/or severe diarrhea or colitis, 
hepatotoxicity and pneumonitis, their risk and severity have 
the potential to be mitigated through proper identification 
and management. 
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